291 related articles for article (PubMed ID: 22954737)
21. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
[TBL] [Abstract][Full Text] [Related]
22. Investigation of the differences in activity between hydroxycycloalkyl N1 substituted pyrazole derivatives as inhibitors of B-Raf kinase by using docking, molecular dynamics, QM/MM, and fragment-based de novo design: study of binding mode of diastereomer compounds.
Caballero J; Alzate-Morales JH; Vergara-Jaque A
J Chem Inf Model; 2011 Nov; 51(11):2920-31. PubMed ID: 22011048
[TBL] [Abstract][Full Text] [Related]
23. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Buckmelter AJ; Ren L; Laird ER; Rast B; Miknis G; Wenglowsky S; Schlachter S; Welch M; Tarlton E; Grina J; Lyssikatos J; Brandhuber BJ; Morales T; Randolph N; Vigers G; Martinson M; Callejo M
Bioorg Med Chem Lett; 2011 Feb; 21(4):1248-52. PubMed ID: 21211972
[TBL] [Abstract][Full Text] [Related]
24. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
25. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
[TBL] [Abstract][Full Text] [Related]
26. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
27. Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Wenglowsky S; Ren L; Grina J; Hansen JD; Laird ER; Moreno D; Dinkel V; Gloor SL; Hastings G; Rana S; Rasor K; Sturgis HL; Voegtli WC; Vigers G; Willis B; Mathieu S; Rudolph J
Bioorg Med Chem Lett; 2014 Apr; 24(8):1923-7. PubMed ID: 24675381
[TBL] [Abstract][Full Text] [Related]
28. The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors.
Tang J; Lackey KE; Dickerson SH
Bioorg Med Chem Lett; 2013 Jan; 23(1):66-70. PubMed ID: 23218715
[TBL] [Abstract][Full Text] [Related]
29. Displacement assay for the detection of stabilizers of inactive kinase conformations.
Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D
J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858
[TBL] [Abstract][Full Text] [Related]
30. Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu S; Gradl SN; Ren L; Wen Z; Aliagas I; Gunzner-Toste J; Lee W; Pulk R; Zhao G; Alicke B; Boggs JW; Buckmelter AJ; Choo EF; Dinkel V; Gloor SL; Gould SE; Hansen JD; Hastings G; Hatzivassiliou G; Laird ER; Moreno D; Ran Y; Voegtli WC; Wenglowsky S; Grina J; Rudolph J
J Med Chem; 2012 Mar; 55(6):2869-81. PubMed ID: 22335519
[TBL] [Abstract][Full Text] [Related]
31. Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors.
Packard GK; Papa P; Riggs JR; Erdman P; Tehrani L; Robinson D; Harris R; Shevlin G; Perrin-Ninkovic S; Hilgraf R; McCarrick MA; Tran T; Fleming Y; Bai A; Richardson S; Katz J; Tang Y; Leisten J; Moghaddam M; Cathers B; Zhu D; Sakata S
Bioorg Med Chem Lett; 2012 Jan; 22(1):747-52. PubMed ID: 22137342
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669
[TBL] [Abstract][Full Text] [Related]
33. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
[TBL] [Abstract][Full Text] [Related]
35. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
36. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors.
Tang J; Hamajima T; Nakano M; Sato H; Dickerson SH; Lackey KE
Bioorg Med Chem Lett; 2008 Aug; 18(16):4610-4. PubMed ID: 18662874
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
38. Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup.
Stellwagen JC; Adjabeng GM; Arnone MR; Dickerson SH; Han C; Hornberger KR; King AJ; Mook RA; Petrov KG; Rheault TR; Rominger CM; Rossanese OW; Smitheman KN; Waterson AG; Uehling DE
Bioorg Med Chem Lett; 2011 Aug; 21(15):4436-40. PubMed ID: 21733693
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives.
Hirose M; Okaniwa M; Miyazaki T; Imada T; Ohashi T; Tanaka Y; Arita T; Yabuki M; Kawamoto T; Tsutsumi S; Sumita A; Takagi T; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
Bioorg Med Chem; 2012 Sep; 20(18):5600-15. PubMed ID: 22883026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
